The evaluation of the clinical efficacy of Prodexyn vaginal suppositories in the treatment of recurrent bacterial vaginosis

Authors

Keywords:

recurrent bacterial vaginosis, biofilms, octenidine, vaginal lactoflora, Prodexyn

Abstract

Background. Bacterial vaginosis (BV) is the most common vaginal infection among women of reproductive age and is associated with an increased risk of sexually transmitted infections and pregnancy complications. First-line antimicrobial treatments are often accompanied by recurrences due to bacterial resistance, biofilm formation, and other factors.
Objective of the study: to evaluate the clinical efficacy, impact on vaginal microbiota, and safety profile of a combination product containing octenidine dihydrochloride and dexpanthenol
(Prodexyn) in the treatment of recurrent BV.
Materials and methods. A prospective study conducted in 2024 and included 192 patients aged 18–36 years with recurrent BV. The participants were divided into two groups: group I – 74 women treated with suppositories based on octenidine dihydrochloride and dexpanthenol, group II – 118 women treated with alternative vaginal antimicrobial drugs (subgroups receiving ternidazole, metronidazole, tinidazole). Efficacy was assessed by symptom resolution, analysis of vaginal microbiota using Hay-Ison criteria, and quality of life using the SF-36 questionnaire.
Results. Group I, treated with octenidine dihydrochloride and dexpanthenol (Prodexyn), demonstrated a higher symptom resolution rate (91.2%) compared to group II (76.3%, p < 0.05). Follow-up PCR analyses confirmed the restoration of normal vaginal biocenosis in 87.5% of patients in group I compared to women in group II: in the ternidazole subgroup, the hazard ratio (HR) was 1.37, 95% confidence interval (CI) was 1.05–1.78 (p = 0.019), in the metronidazole subgroup HR = 1.63, 95% CI = 1.14–2.33 (p = 0.007), in the tinidazole subgroup HR = 1.62, 95% CI = 1.12–2.35 (p = 0.009). The safety profile was favorable, with minimal adverse effects reported.
Conclusions. The combination product containing octenidine dihydrochloride and dexpanthenol (Prodexyn) demonstrates high clinical efficacy, promotes the restoration of normal vaginal microbiota, and has a favorable safety profile. These findings support its use as an effective approach in the treatment of recurrent bacterial vaginosis.

Author Biographies

D.G. Konkov, Vinnytsya National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Department of Obstetrics and Gynecology No 1

A.V. Starovier, Vinnytsia National Pirogov Medical University, Vinnytsia

PhD, associate professor, Department of Obstetrics and Gynecology No 1

O.V. Bulavenko, Vinnytsia National Pirogov Medical University, Vinnytsia

MD, professor, head of the Department of Оbstetrics and Gynecology No 2

N.V. Dan, Vinnytsya National Pirogov Memorial Medical University, Vinnytsia

Assistant, Department of Obstetrics and Gynecology No 1

O.V. Buran, Vinnytsya National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor, Department of Obstetrics and Gynecology No 1

References

  1. Tatarchuk TF, Kalugina LV, Petrova GA, et all. Vaginal discharge syndrome. Problem with many unknowns. Reproductive endocrinology2020;53:94–100. DOI: 10.18370/2309-4117.2020.53.94-100
  2. Artyomenko V, Nastradina N, Chikanchi V, Iacoban S. Vaginal microbiome and neoplasms of the female reproductive system: a marker or a factor of influence? Reproductive endocrinology. 2024;71:84–92. DOI: 10.18370/2309-4117.2024.71.84-92.
  3. Carter KA, Fischer MD, Petrova MI, Balkus JE. Epidemiologic Evidence on the Role of Lactobacillus iners in Sexually Transmitted Infections and Bacterial Vaginosis: A Series of Systematic Reviews and Meta-Analyses. Sex Transm Dis. 2023 Apr 1;50(4):224–35. DOI: 10.1097/OLQ.0000000000001744.
  4. Fan Y, Gu Y, Xian Y, et all. Efficacy and safety of different drugs for the treatment of bacterial vaginosis: a systematic review and network meta-analysis. Front Cell Infect Microbiol. 2024 Oct 11;14:1402346. DOI: 10.3389/fcimb.2024.1402346.
  5. Maksimovic Celicanin M, Haahr T, Humaidan P, Skafte-Holm A. Vaginal dysbiosis – the association with reproductive outcomes in IVF patients: a systematic review and meta-analysis. Curr Opin Obstet Gynecol. 2024 Jun 1;36(3):155–64. DOI: 10.1097/GCO.0000000000000953.
  6. Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis 2019;46:304–11.DOI: 10.1097/OLQ.0000000000000972
  7. Farr A, Swidsinski S, Surbek D, et.all. Bacterial Vaginosis: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/028, June 2023). Geburtshilfe Frauenheilkd. 2023 Nov 3;83(11):1331–49. DOI: 10.1055/a-2169-8539.
  8. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it’s associated resistance patterns. Microb Pathog. 2019 Feb;127:21–30. DOI: 10.1016/j.micpath.2018.11.046.
  9. Muzny CA, Sobel JD. The role of antimicrobial resistance in refractory and recurrent bacterial vaginosis and current recommendations for treatment. Antibiotics. 2022;11(4). DOI:10.3390/antibiotics11040500.
  10. Karpiński TM, Korbecka-Paczkowska M, Ożarowski M, et all. Adaptation to sodium hypochlorite and potassium permanganate may lead to their ineffectiveness against Candida albicans. Pharmaceuticals (Basel). 2024 Nov 17;17(11):1544. DOI: 10.3390/ph17111544.
  11. Dittmann K, Schmidt T, Müller G, et al. Susceptibility of livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) to chlorhexidine digluconate, octenidine dihydrochloride, polyhexanide, PVP-iodine and triclosan in comparison to hospital-acquired MRSA (HA-MRSA) and community-aquired MRSA (CA-MRSA): a standardized comparison. Antimicrob Resist Infect Control. 2019 Jul 22;8:122. DOI: 10.1186/s13756-019-0580-9.
  12. Finucane TE. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020 Aug 20;383(8):791. DOI: 10.1056/NEJMc2021832.
  13. Gao M, Manos J, Whiteley G, Zablotska-Manos I. Antibiofilm agents for the treatment and prevention of bacterial vaginosis: a systematic narrative review. J Infect Dis. 2024 Sep 23;230(3):e508-e517. DOI: 10.1093/infdis/jiae134.
  14. Sousa LGV, Pereira SA, Cerca N. Fighting polymicrobial biofilms in bacterial vaginosis. Microb Biotechnol. 2023 Jul;16(7):1423–37. DOI: 10.1111/1751-7915.14261.
  15. Swidsinski A, Loening-Baucke V, Swidsinski S, et. al. Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch. Gynecol. Obstet., 2015 Mar, 291(3): 605–9. DOI: 10.1007/s00404-014-3484-1.
  16. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015 Jul 29;15:292. DOI: 10.1186/s12879-015-1027-4. PMID: 26219949; PMCID: PMC4518586.
  17. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016 Aug 15;214 Suppl 1(Suppl 1):S14–20. DOI: 10.1093/infdis/jiw159.
  18. Gaspar C, Rolo J, Cerca N, et all. Dequalinium chloride effectively disrupts bacterial vaginosis (BV) Gardnerella spp. Biofilms. Pathogens 2021, 10, 261. DOI: 10.3390/pathogens10030261.
  19. Müller G, Langer J, Siebert J, Kramer A. Residual antimicrobial effect of chlorhexidine digluconate and octenidine dihydrochloride on reconstructed human epidermis. Skin Pharmacol. Physiol., 2014, 27(1): 1–8. DOI: 10.1159/000350172.
  20. Xu Z, Lai Y, Wu D et al. Antibacterial effects and biocompatibility of titania nanotubes with octenidine dihydrochloride/poly(lactic-coglycolic acid). Biomed. Res. Int., 2015, 2015: 836939. DOI: 10.1155/2015/836939.
  21. Novakov Mikic A, Budakov D. Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch Gynecol Obstet. 2010 Jul;282(1):43–7. DOI: 10.1007/s00404-009-1241-7.
  22. Briese V, Neumann G, Waldschläger J, et al. Efficacy and tolerability of a local acting antiseptic agent in the treatment of vaginal dysbiosis during pregnancy. Arch Gynecol Obstet. 2011 Mar;283(3):585–90. DOI: 10.1007/s00404-010-1414-4.
  23. Akulina O. Effectiveness of local application of antiseptic with octenidin dihydrochloride molecule in smoking women with ASC-US and LSIL. Reproductive endocrinology. 2021;58:90–6. DOI: 10.18370/2309-4117.2021.58.90-96.
  24. Verstraelen H, Loening-Baucke V, Swidsinski S, et al P1.028.Treatment of Recurrent Bacterial Vaginosis with Octenidine Dihydrochloride. Sexually Transmitted Infections 2013;89:A82. DOI:10.1136/sextrans-2013-051184.0249
  25. Schaumburg T, Köhler N, Breitenstein Y, et al EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study. Intensive Care Med. 2024 Dec;50(12):2073–82. DOI: 10.1007/s00134-024-07667-2.
  26. Pyrohova VI, Shurpyak S.O. Modern tendency of prevention and treatment of infectious processes of the lower genital tract. Reproductive endocrinology. 2019;50:18–21. DOI: 10.18370/2309-4117.2019.50.18-21.

Downloads

Published

2024-12-31

How to Cite

Konkov, D., Starovier, A., Bulavenko, O., Dan, N. ., & Buran, O. (2024). The evaluation of the clinical efficacy of Prodexyn vaginal suppositories in the treatment of recurrent bacterial vaginosis. REPRODUCTIVE ENDOCRINOLOGY, (75), 37–43. Retrieved from https://reproduct-endo.com/article/view/322527

Issue

No. 75 (2024)

Section

Inflammatory diseases

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.